On the basis of these previous studies suggesting the roles of IL-6 in cervical cancer development and progression, and the fact that cervical cancer cells have high EGFR expression, the discovery of agents that can be used in combination to suppress both IL-6/STAT3 and EGFR signal transduction pathways would possibly result in better treatment outcomes for cervical cancer. The gene discussed is IL6; the disease is cervical carcinoma.